Cambrex announces acquisition of IEP GmbH

Cambrex Corporation (NYSE: CBM) announced it has acquired IEP GmbH (“IEP”), a privately held company that is a leader in the field of industrial biocatalysis.  IEP is located in Wiesbaden, Germany and offers cost effective customized biocatalytic process development and sales of enzymes to the pharmaceutical industry, with the ability to utilize its tool box of over 100 proprietary biocatalytic enzymes.  IEP “bioreduction” technologies have been successfully used in numerous commercialized processes.

“In combination with our existing chiral chemistry business, the acquisition of IEP will result in Cambrex being able to offer a broad biocatalysis platform to the pharmaceutical industry.  We are very excited about the future growth of this business, as IEP has demonstrated the introduction of a “green” biocatalytic step in chemical synthesis that can provide significant benefits resulting in the cost efficient, commercial scale production of enantiomerically pure chemical products and intermediates.  IEP has assembled, under the leadership of Dr. Antje Gupta, a strong group of highly skilled scientists and built a successful business based on its proprietary technology and intellectual property.  We are looking forward to working with the IEP team to expand their business development efforts through the existing Cambrex channels to market,” commented Steven Klosk, President & CEO of Cambrex Corporation.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Researchers discover a new mechanism of resistance to KRAS inhibitors in pancreas cancer